89bio, INC

89bio, Inc. has completed its merger with Roche Holdings, Inc., becoming a wholly-owned subsidiary and initiating its delisting from The Nasdaq Global Market.

Roche Holdings, Inc. will acquire 89bio, Inc. for $14.50 per share in cash plus a contingent value right of up to $6.00 per share, totaling up to $3.5 billion.

89bio, Inc. announced Q2 2025 financial results and provided updates on its Phase 3 trials for pegozafermin in MASH and SHTG, with key data expected in 2026-2028.

89bio, Inc. announced that all director nominees were elected and all proposals, including the ratification of KPMG LLP as independent auditor and the advisory vote on executive compensation, were approved at its 2025 Annual Meeting of Stockholders.

89bio announces its Q1 2025 financial results, highlighting progress in Phase 3 trials for MASH and SHTG, and a strong cash position following a recent equity offering.

89bio provides an update on its corporate presentation, emphasizing the potential of Pegozafermin in treating MASH with advanced fibrosis and compensated cirrhosis, as well as severe hypertriglyceridemia (SHTG).

89bio, a clinical-stage biopharmaceutical company, reported a significantly wider net loss in Q2 2025 due to increased R&D and G&A expenses, while advancing its lead MASH and SHTG product candidates.

89bio reports its financial results for the first quarter of 2025, highlighting progress in its MASH and SHTG programs and a strong cash position.

89bio, Inc. released its third quarter 2024 financial results, detailing increased research and development spending and a net loss, while also highlighting progress in its clinical programs.

89bio, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical development and strategic collaborations.

89bio, a clinical-stage biopharmaceutical company, announced its first quarter 2024 financial results, highlighting increased R&D spending and progress in clinical trials for pegozafermin.

89bio, a clinical-stage biopharmaceutical company, provides an update on its financial results for the year ended December 31, 2024, and highlights the advancement of its lead product candidate, pegozafermin, in clinical trials for MASH and SHTG.

89bio, Inc.'s 10-K filing details its capital structure, regulatory environment, and ongoing clinical programs for pegozafermin.

RA Capital Management and its affiliated funds disposed of their holdings in 89bio, Inc. following its acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

Kathleen LaPorte's stock options in 89bio, Inc. were converted into cash and contingent value rights following the company's acquisition by Roche Holdings, Inc. for $14.50 per share plus CVRs.

89bio, Inc. director Michael R. Hayden disposed of all his common stock and stock options following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

89bio's Chief Financial Officer, Ryan Martins, reported significant equity transactions, including RSU settlement and disposal of shares and options, as part of the company's acquisition by Roche Holdings.

89bio Director Steven Altschuler disposed of all his stock options as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

89bio, Inc. CEO Rohan Palekar disposed of all his common stock and derivative securities following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR per share.

89bio, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 28, 2025, with voting matters including the election of directors, ratification of the appointment of KPMG LLP, and advisory approval of executive compensation.

89bio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 28, 2025, to vote on director elections, auditor ratification, and executive compensation.

89bio, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 29, 2024, and encourages stockholders to review proxy materials and vote on key proposals.

89bio, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 29, 2024, to vote on director elections, auditor ratification, executive compensation, and the frequency of executive compensation votes.

RA Capital Management has fully divested its holdings in 89bio, Inc. following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

Adage Capital Management and its principals have fully divested their 13.1 million shares in 89bio, Inc. through a tender offer at $14.50 cash per share plus a contingent value right.

Adage Capital Management, L.P. and its principals have disclosed a 6.13% beneficial ownership stake in 89bio, Inc., acquired for investment purposes in anticipation of the company's merger with Roche Holdings, Inc.

RA Capital Management and its affiliates have reaffirmed their aggregate 13.7% beneficial ownership in 89bio, Inc., reflecting an updated total outstanding share count for the biopharmaceutical company.

RA Capital Management, L.P. and its affiliates have increased their beneficial ownership in 89bio, Inc. to 15.1% of outstanding common stock after purchasing shares in the company's recent public offering.

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in 89bio, Inc., holding 0% of common stock as of December 31, 2025.

Pentwater Capital Management LP and Matthew Halbower have reported a complete divestment of their 7.9% stake in 89bio, Inc. as of the filing date.

Deep Track Capital, along with its affiliates, has reported a 6.31% beneficial ownership stake in 89bio, Inc., holding 9,356,171 shares of common stock.

Suvretta Capital Management, LLC and Aaron Cowen have reported a 5.6% beneficial ownership stake in 89bio, Inc. common stock as of September 30, 2025.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a reduction in its beneficial ownership in 89bio, Inc. common stock to 3.6%.

Janus Henderson Group PLC has increased its beneficial ownership in 89bio, Inc. to 14.2% of common stock, holding over 20.7 million shares.